Valeant buys Raleigh's Salix Pharmaceuticals for $10 billion in cash

Salix Pharmaceuticals (NASDAQ:SLXP) has agreed to be acquired by Valeant Pharmaceuticals International (NYSE:VRX) for $158 per share, or about $10 billion in cash, the companies announced Sunday. Salix is Raleigh's largest homegrown pharmaceutical company, but it has gone through some peaks and valleys in the past few months. In 2014, Salix was rumored as an acquisition candidate of Botox maker Allergan (NYSE:AGN), but talks broke apart partly because Salix had misreported inventory levels of its…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news